Advertisement
UK markets close in 4 hours 5 minutes

  • FTSE 100

    8,084.47
    +39.66 (+0.49%)
     

  • FTSE 250

    19,796.30
    -3.42 (-0.02%)
     

  • AIM

    754.85
    -0.02 (-0.00%)
     

  • GBP/EUR

    1.1637
    +0.0009 (+0.08%)
     

  • GBP/USD

    1.2439
    -0.0013 (-0.11%)
     

  • Bitcoin GBP

    53,368.90
    +218.32 (+0.41%)
     

  • CMC Crypto 200

    1,434.89
    +10.79 (+0.76%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    82.72
    -0.64 (-0.77%)
     

  • GOLD FUTURES

    2,327.80
    -14.30 (-0.61%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,194.99
    +57.34 (+0.32%)
     

  • CAC 40

    8,133.81
    +28.03 (+0.35%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

How Much Is BioNTech's Increased Vaccine Production Really Worth?

Brian Orelli, PhD and Keith Speights, The Motley Fool
·4-min read

BioNTech (NASDAQ: BNTX) recently raised guidance for the number of doses of its coronavirus vaccine that the biotech thinks it'll be able to produce this year. In this video from Motley Fool Live, recorded on April 5, Fool.com contributors Brian Orelli and Keith Speights discuss whether the increase will actually help the German drugmaker. Unfortunately, between a supply glut and the inability for developing companies to pay full price, the added capacity may not help BioNTech's bottom line that much.

Continue reading